Nadolol is under clinical development by Invion and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nadolol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nadolol overview

Nadolol (INV-102) is under development for the treatment of smoking cessation in a patient with chronic bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma. It is administered through oral and inhalational routes. It may be a steroid-sparing beta inverse agonist. Beta-blockers reduce the flow of air through the bronchial tubes in the lung. The drug candidate complements low-dose inhaled corticosteroids and improves the efficacy and safety of long-acting beta agonists.

It was also under development for the treatment of smoking cessation.

Invion overview

Invion is a life sciences company that develops products for the treatment of inflammatory diseases such as chronic inflammatory, airway disease and inflammation caused by autoimmune disease. The company’s pipeline products include INV102 nadolol, a beta adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium for the treatment of chronic inflammatory airway diseases; INV103 ala-Cpn10, a naturally occuring human protein for the treatment of chronic inflammation; and INV104 zafirlukast, a leukotriene receptor antagonist for the prevention of asthma attacks. Invion also conducts clinical development programs for developing zafirlukast as a novel non-steroidal, anti-inflammatory treatment to prevent asthma attacks. The company has operations in Melbourne, Australia and Delaware, the US. Invion is headquartered in Melbourne, Victoria, Australia.

For a complete picture of Nadolol’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.